Physician profile
Pal Lekaj
NPI 1366407546
$2,299.71
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,052 · 2020: $222 · 2021: $14.00 · 2022: $11.75.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $415.59 | 2019-2020 | |
| Corcept Therapeutics | $191.16 | 2019 | |
| Janssen Pharmaceuticals, INC | $191.05 | 2019 | |
| Abbvie INC. | $167.61 | 2019-2020 | |
| Pfizer INC. | $163.93 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $145.16 | 2019-2020 | |
| Amgen INC. | $143.34 | 2019 | |
| Glaxosmithkline, LLC. | $111.50 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.76 | 2019 | |
| Novartis Pharmaceuticals Corporation | $106.62 | 2019-2020 | |
| Electromed, INC. | $91.99 | 2019 | |
| Mylan Specialty L.P. | $70.14 | 2019-2020 | |
| Ibsa Pharma INC. | $61.59 | 2019-2020 | |
| Shire North American Group INC | $60.99 | 2019 | |
| Lilly USA, LLC | $45.88 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $27.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.67 | 2019-2020 | |
| Gilead Sciences, INC. | $24.01 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.23 | 2019 | |
| Sunovion Pharmaceuticals INC. | $19.81 | 2019 | |
| Grifols USA, LLC | $19.54 | 2019 | |
| Seqirus USA INC | $17.16 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.10 | 2020 | |
| Novo Nordisk INC | $13.18 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.17 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.37 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pal Lekaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.